エクソソーム診断・治療市場：用途別、製品別、エンドユーザー別：世界の機会分析と産業予測、2021～2030年

エクソソーム診断・治療市場は、2020年には2億2,434万米ドルと評価され、2021年から2030年にかけてCAGR 29.4％で成長し、2030年には29億米ドルに達すると推定されています。

エクソソームの用途は、免疫反応、ウイルスの病原性、妊娠、心血管疾患、中枢神経系関連疾患、がんの進行に関連しています。エクソソームは、診断と治療の2つの用途で使用されます。エクソソーム診断・治療技術に使用される製品には、装置、試薬、ソフトウェアの3つのタイプがあります。

さらに、中国やインドなどの新興国は、この市場に大きな成長機会をもたらすと期待されています。エクソソーム診断・治療市場は、用途、製品、エンドユーザー、地域によって区分されます。用途別では、診断用途と治療用途に二分されます。製品別では、装置、試薬、ソフトウェアに分類されます。エンドユーザー別では、がん研究所、病院、診断センター、その他（医科大学、非営利団体）に区分されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ・中東・アフリカで分析されます。北米は2020年に市場を席巻し、研究開発投資の増加、エクソソーム分離手順の技術進歩、がん罹患率の上昇などの要因により、予測期間中もその優位性を維持すると予想されます。さらに、アジア太平洋は、発展途上国に対する主な参入企業の関心の高まり、臨床研究および試験のアウトソーシングの増加、人々の健康に対する意識と関心の高まり、がんおよびその他の慢性疾患の発生率の急増により、最大の成長可能性を持つ地域として浮上すると予想されています。

本レポートでは、エクソソーム診断・治療市場で事業を展開する主要企業（Aethlon Medical, Inc.（米国）、Exosome Diagnostics Inc.（米国）、NanoSomix Inc.（米国）、Thermo Fisher Scientific Inc.（英国）、System Biosciences Inc.（米国）、NX Pharmagen（米国）、Sistemic Inc.（英国）、Capricor Therapeutics（米国）、Exiqon A/S（デンマーク））。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

• 市場の定義と範囲
• 主な調査結果
  • 影響要因
  • 主な投資機会
• ポーターのファイブフォース分析
• 市場力学
  • 促進要因
    • 慢性疾患の増加
    • がんの有病率の増加
    • 高齢者人口の増加
  • 抑制要因
    • エクソソーム診断・治療技術の製品認可の欠如
  • 機会
    • 主要戦略の採用の増加
• COVID-19市場への影響分析

第4章 エクソソーム診断・治療市場：用途別

• 概要
• 診断
• 治療

第5章 エクソソーム診断・治療市場：製品別

• 概要
• 装置
• 試薬
• ソフトウェア

第6章 体外診断薬・治療薬市場：エンドユーザー別

• 概要
• がん研究所
• 病院
• 診断センター
• その他

第7章 エクソソーム診断・治療市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他
• アジア太平洋
  • 日本
  • 中国
  • その他
• ラテンアメリカ・中東・アフリカ
  • ブラジル
  • サウジアラビア
  • 南アフリカ
  • その他

第8章 競争情勢

• イントロダクション
• 主要成功戦略
• 主要10企業の製品マッピング
• 競合ダッシュボード
• 競合ヒートマップ
• 主要企業のポジショニング、2020年

第9章 企業プロファイル

• Aethlon Medical, Inc.
• Exosome Diagnostic, Inc.
• NanoSomix, Inc
• Thermo Fisher Scientific, Inc.
• Malvern Instruments Ltd
• System Biosciences, Inc
• NX Pharmagen, Inc.
• Sistemic Ltd
• Capricor Therapeutics, Inc.
• Exiqon A/S

LIST OF TABLES

• TABLE 01. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 02. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY REGION, 2020-2030 ($MILLION)
• TABLE 03. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY REGION, 2020-2030 ($MILLION)
• TABLE 04. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 05. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY REGION, 2020-2030 ($MILLION)
• TABLE 06. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY REGION, 2020-2030 ($MILLION)
• TABLE 07. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY REGION, 2020-2030 ($MILLION)
• TABLE 08. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 09. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY REGION, 2020-2030 ($MILLION)
• TABLE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY REGION, 2020-2030 ($MILLION)
• TABLE 11. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY REGION, 2020-2030 ($MILLION)
• TABLE 12. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
• TABLE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION, 2020-2030 ($MILLION)
• TABLE 14. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 15. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 16. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 17. NORTH AMERICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
• TABLE 18. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 19. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 20. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 21. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 22. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 23. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 24. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 26. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 27. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 28. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 29. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 30. EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
• TABLE 31. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 32. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 33. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 34. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 35. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 36. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 37. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 38. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 39. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 40. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 41. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 42. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 43. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 44. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 45. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 46. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 47. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 48. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 49. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 50. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 51. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 52. ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
• TABLE 53. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 54. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 55. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 56. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 57. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 58. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 59. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 60. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 61. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 62. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 63. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 64. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 65. LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY COUNTRY, 2020-2030 ($MILLION)
• TABLE 66. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 67. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 68. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 69. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 70. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 71. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 72. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 73. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 74. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 75. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020-2030 ($MILLION)
• TABLE 76. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020-2030 ($MILLION)
• TABLE 77. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020-2030 ($MILLION)
• TABLE 78. AETHLON MEDICAL, INC.: KEY EXECUTIVES
• TABLE 79. AETHLON MEDICAL, INC.: COMPANY SNAPSHOT
• TABLE 80. AETHLON MEDICAL, INC.: PRODUCT SEGMENTS
• TABLE 81. AETHLON MEDICAL, INC.: PRODUCT PORTFOLIO
• TABLE 82. AETHLON MEDICAL, INC.: KEY STRATERGIES
• TABLE 83. EXOSOME DIAGNOSTIC, INC.: KEY EXECUTIVES
• TABLE 84. EXOSOME DIAGNOSTIC, INC.: COMPANY SNAPSHOT
• TABLE 85. EXOSOME DIAGNOSTIC, INC.: PRODUCT SEGMENTS
• TABLE 86. EXOSOME DIAGNOSTIC, INC.: PRODUCT PORTFOLIO
• TABLE 87. EXOSOME DIAGNOSTIC, INC.: KEY STRATERGIES
• TABLE 88. NANOSOMIX, INC: KEY EXECUTIVES
• TABLE 89. NANOSOMIX, INC: COMPANY SNAPSHOT
• TABLE 90. NANOSOMIX, INC: PRODUCT SEGMENTS
• TABLE 91. NANOSOMIX, INC: PRODUCT PORTFOLIO
• TABLE 92. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
• TABLE 93. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
• TABLE 94. THERMO FISHER SCIENTIFIC, INC.: PRODUCT SEGMENTS
• TABLE 95. THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
• TABLE 96. MALVERN INSTRUMENTS LTD: KEY EXECUTIVES
• TABLE 97. MALVERN INSTRUMENTS LTD: COMPANY SNAPSHOT
• TABLE 98. MALVERN INSTRUMENTS LTD: PRODUCT SEGMENTS
• TABLE 99. MALVERN INSTRUMENTS LTD: PRODUCT PORTFOLIO
• TABLE 100. SYSTEM BIOSCIENCES, INC: KEY EXECUTIVES
• TABLE 101. SYSTEM BIOSCIENCES, INC: COMPANY SNAPSHOT
• TABLE 102. SYSTEM BIOSCIENCES, INC: PRODUCT SEGMENTS
• TABLE 103. SYSTEM BIOSCIENCES, INC: SERVICE SEGMENTS
• TABLE 104. SYSTEM BIOSCIENCES, INC: PRODUCT PORTFOLIO
• TABLE 105. NX PHARMAGEN, INC.: KEY EXECUTIVES
• TABLE 106. NX PHARMAGEN, INC.: COMPANY SNAPSHOT
• TABLE 107. NX PHARMAGEN, INC.: PRODUCT SEGMENTS
• TABLE 108. NX PHARMAGEN, INC.: PRODUCT PORTFOLIO
• TABLE 109. SISTEMIC LTD: KEY EXECUTIVES
• TABLE 110. SISTEMIC LTD: COMPANY SNAPSHOT
• TABLE 111. SISTEMIC LTD: PRODUCT SEGMENTS
• TABLE 112. SISTEMIC LTD: PRODUCT PORTFOLIO
• TABLE 113. CAPRICOR THERAPEUTICS, INC.: KEY EXECUTIVES
• TABLE 114. CAPRICOR THERAPEUTICS, INC.: COMPANY SNAPSHOT
• TABLE 115. CAPRICOR THERAPEUTICS, INC.: SERVICE SEGMENTS
• TABLE 116. CAPRICOR THERAPEUTICS, INC.: PRODUCT PORTFOLIO
• TABLE 117. EXIQON A/S: KEY EXECUTIVES
• TABLE 118. EXIQON A/S: COMPANY SNAPSHOT
• TABLE 119. EXIQON A/S: PRODUCT SEGMENTS
• TABLE 120. EXIQON A/S: PRODUCT PORTFOLIO

LIST OF FIGURES

• FIGURE 01. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030
• FIGURE 02. SEGMENTATION OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET,2020-2030
• FIGURE 03. TOP INVESTMENT POCKETS IN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET (2021-2030)
• FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
• FIGURE 05. LOW THREAT OF NEW ENTRANTS
• FIGURE 06. LOW THREAT OF SUBSTITUTES
• FIGURE 07. LOW INTENSITY OF RIVALRY
• FIGURE 08. LOW BARGAINING POWER OF BUYERS
• FIGURE 09. GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
• FIGURE 10. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION, 2020(%)
• FIGURE 11. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC, BY COUNTRY 2020 AND 2030(%)
• FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR THERAPEUTIC, BY COUNTRY 2020 AND 2030(%)
• FIGURE 13. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT, 2020(%)
• FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR INSTRUMENT, BY COUNTRY 2020 AND 2030(%)
• FIGURE 15. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR REAGENT, BY COUNTRY 2020 AND 2030(%)
• FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR SOFTWARE, BY COUNTRY 2020 AND 2030(%)
• FIGURE 17. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER, 2020(%)
• FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR CANCER INSTITUTE, BY COUNTRY 2020 AND 2030(%)
• FIGURE 19. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR HOSPITAL, BY COUNTRY 2020 AND 2030(%)
• FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR DIAGNOSTIC CENTER, BY COUNTRY 2020 AND 2030(%)
• FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FOR OTHERS, BY COUNTRY 2020 AND 2030(%)
• FIGURE 22. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET BY REGION, 2020(%)
• FIGURE 23. U.S. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 24. CANADA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 25. MEXICO EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 26. GERMANY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 27. FRANCE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 28. U.K. EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 29. ITALY EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 30. SPAIN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 31. REST OF EUROPE EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 32. JAPAN EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 33. CHINA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 34. REST OF ASIA-PACIFIC EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 35. BRAZIL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 36. SAUDI ARABIA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 37. SOUTH AFRICA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 38. REST OF LAMEA EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, 2020-2030 ($MILLION)
• FIGURE 39. TOP WINNING STRATEGIES, BY YEAR
• FIGURE 40. TOP WINNING STRATEGIES, BY DEVELOPMENT
• FIGURE 41. TOP WINNING STRATEGIES, BY COMPANY
• FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
• FIGURE 43. COMPETITIVE DASHBOARD
• FIGURE 44. COMPETITIVE HEATMAP: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET
• FIGURE 45. TOP PLAYER POSITIONING, 2020
• FIGURE 46. THERMO FISHER SCIENTIFIC, INC.: NET REVENUE, 2019-2021 ($MILLION)
• FIGURE 47. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
• FIGURE 48. THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE BY REGION, 2021 (%)
• FIGURE 49. CAPRICOR THERAPEUTICS, INC.: NET REVENUE, 2020-2022 ($MILLION)

According to a new report published by Allied Market Research, titled, "Exosome Diagnostic and Therapeutic Market," The exosome diagnostic and therapeutic market was valued at $224.34 million in 2020, and is estimated to reach $2.9 billion by 2030, growing at a CAGR of 29.4% from 2021 to 2030. Exosomes applications are associated with immune responses, viral pathogenicity, pregnancy, cardiovascular diseases, central nervous system-related diseases, and cancer progression. Exosomes are used in two applications, which includes diagnostic and therapeutic. There are three types of products used in exosomes diagnostic and therapeutic technique, which include instrument, reagent, and software.

Furthermore, the developing countries, such as China and India are expected to provide huge growth opportunities to this market. The exosomes diagnostic and therapeutic market is segmented on the basis of application, product, end user, and region. As per the application, it is bifurcated into diagnostic and therapeutic applications. By the product, it is classified into instrument, reagents, and software. Depending on end user, it is segmented into cancer institute, hospitals, diagnostic centers, and others (medical universities and not-for-profit organizations). Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. North America dominated the market in 2020, and is expected to maintain its dominance throughout the forecast period, due to factors, such as increase in R&D investments, technological advancement in the exosomes isolation procedures, and rise in incidence of cancer. In addition, Asia-Pacific is expected to emerge as the area with maximum growth potential due to the increase in focus of key players on developing countries, rise in clinical research & trial outsourcing, growth in awareness & focus on health of the people, and surge in incidence of cancer & other chronic diseases.

The report provides a comprehensive analysis of the key players operating in the exosome diagnostics and therapeutic market, including Aethlon Medical, Inc. (U.S.), Exosome Diagnostics Inc. (U.S.), NanoSomix Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Malvern Instruments Ltd. (UK), System Biosciences Inc. (U.S.), NX Pharmagen (U.S.), Sistemic Inc. (UK), Capricor Therapeutics (U.S.), and Exiqon A/S (Denmark).

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the exosome diagnostic and therapeutic market analysis from 2020 to 2030 to identify the prevailing exosome diagnostic and therapeutic market opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the exosome diagnostic and therapeutic market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global exosome diagnostic and therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

• Product Benchmarking / Product specification and applications
• Market share analysis of players by products/segments
• New Product Development/ Product Matrix of Key Players
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Average Selling Price Analysis / Price Point Analysis
• Expanded list for Company Profiles
• Historic market data
• SWOT Analysis

Key Market Segments

By Application

• Diagnostic
• Therapeutic

By Product

• Instrument
• Reagent
• Software

By End User

• Cancer Institute
• Hospital
• Diagnostic Center
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Thermo Fisher Scientific, Inc.
• Malvern Instruments Ltd
• NX Pharmagen, Inc.
• Sistemic Ltd
• Exosome Diagnostic, Inc.
• Capricor Therapeutics, Inc.
• NanoSomix, Inc
• System Biosciences, Inc
• Exiqon A/S
• Aethlon Medical, Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research Methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in prevalence of chronic diseases
    • 3.4.1.2. Increase in prevalence of cancer
    • 3.4.1.3. Rise in number of geriatric populations

• 3.4.2. Restraints
  • 3.4.2.1. Lack of product approvals for exosome diagnostic and therapeutic technique

• 3.4.3. Opportunities
  • 3.4.3.1. Rise in adoption of key strategies

• 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY APPLICATION

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Diagnostic
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Therapeutic
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country

CHAPTER 5: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY PRODUCT

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Instrument
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Reagent
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Software
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country

CHAPTER 6: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Cancer Institute
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Hospital
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country
• 6.4. Diagnostic Center
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by region
  • 6.4.3. Market share analysis by country
• 6.5. Others
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by region
  • 6.5.3. Market share analysis by country

CHAPTER 7: EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key trends and opportunities
  • 7.2.2. Market size and forecast, by Application
  • 7.2.3. Market size and forecast, by Product
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Key market trends, growth factors and opportunities
    • 7.2.5.1.2. Market size and forecast, by Application
    • 7.2.5.1.3. Market size and forecast, by Product
    • 7.2.5.1.4. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Key market trends, growth factors and opportunities
    • 7.2.5.2.2. Market size and forecast, by Application
    • 7.2.5.2.3. Market size and forecast, by Product
    • 7.2.5.2.4. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Key market trends, growth factors and opportunities
    • 7.2.5.3.2. Market size and forecast, by Application
    • 7.2.5.3.3. Market size and forecast, by Product
    • 7.2.5.3.4. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key trends and opportunities
  • 7.3.2. Market size and forecast, by Application
  • 7.3.3. Market size and forecast, by Product
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Key market trends, growth factors and opportunities
    • 7.3.5.1.2. Market size and forecast, by Application
    • 7.3.5.1.3. Market size and forecast, by Product
    • 7.3.5.1.4. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Key market trends, growth factors and opportunities
    • 7.3.5.2.2. Market size and forecast, by Application
    • 7.3.5.2.3. Market size and forecast, by Product
    • 7.3.5.2.4. Market size and forecast, by End User
    • 7.3.5.3. U.K.
    • 7.3.5.3.1. Key market trends, growth factors and opportunities
    • 7.3.5.3.2. Market size and forecast, by Application
    • 7.3.5.3.3. Market size and forecast, by Product
    • 7.3.5.3.4. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Key market trends, growth factors and opportunities
    • 7.3.5.4.2. Market size and forecast, by Application
    • 7.3.5.4.3. Market size and forecast, by Product
    • 7.3.5.4.4. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Key market trends, growth factors and opportunities
    • 7.3.5.5.2. Market size and forecast, by Application
    • 7.3.5.5.3. Market size and forecast, by Product
    • 7.3.5.5.4. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Key market trends, growth factors and opportunities
    • 7.3.5.6.2. Market size and forecast, by Application
    • 7.3.5.6.3. Market size and forecast, by Product
    • 7.3.5.6.4. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key trends and opportunities
  • 7.4.2. Market size and forecast, by Application
  • 7.4.3. Market size and forecast, by Product
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Key market trends, growth factors and opportunities
    • 7.4.5.1.2. Market size and forecast, by Application
    • 7.4.5.1.3. Market size and forecast, by Product
    • 7.4.5.1.4. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Key market trends, growth factors and opportunities
    • 7.4.5.2.2. Market size and forecast, by Application
    • 7.4.5.2.3. Market size and forecast, by Product
    • 7.4.5.2.4. Market size and forecast, by End User
    • 7.4.5.3. Rest of Asia-Pacific
    • 7.4.5.3.1. Key market trends, growth factors and opportunities
    • 7.4.5.3.2. Market size and forecast, by Application
    • 7.4.5.3.3. Market size and forecast, by Product
    • 7.4.5.3.4. Market size and forecast, by End User
• 7.5. LAMEA
  • 7.5.1. Key trends and opportunities
  • 7.5.2. Market size and forecast, by Application
  • 7.5.3. Market size and forecast, by Product
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Key market trends, growth factors and opportunities
    • 7.5.5.1.2. Market size and forecast, by Application
    • 7.5.5.1.3. Market size and forecast, by Product
    • 7.5.5.1.4. Market size and forecast, by End User
    • 7.5.5.2. Saudi Arabia
    • 7.5.5.2.1. Key market trends, growth factors and opportunities
    • 7.5.5.2.2. Market size and forecast, by Application
    • 7.5.5.2.3. Market size and forecast, by Product
    • 7.5.5.2.4. Market size and forecast, by End User
    • 7.5.5.3. South Africa
    • 7.5.5.3.1. Key market trends, growth factors and opportunities
    • 7.5.5.3.2. Market size and forecast, by Application
    • 7.5.5.3.3. Market size and forecast, by Product
    • 7.5.5.3.4. Market size and forecast, by End User
    • 7.5.5.4. Rest of LAMEA
    • 7.5.5.4.1. Key market trends, growth factors and opportunities
    • 7.5.5.4.2. Market size and forecast, by Application
    • 7.5.5.4.3. Market size and forecast, by Product
    • 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product Mapping of Top 10 Player
• 8.4. Competitive Dashboard
• 8.5. Competitive Heatmap
• 8.6. Top player positioning, 2020

CHAPTER 9: COMPANY PROFILES

• 9.1. Aethlon Medical, Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key Executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Key strategic moves and developments
• 9.2. Exosome Diagnostic, Inc.
  • 9.2.1. Company overview
  • 9.2.2. Key Executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Key strategic moves and developments
• 9.3. NanoSomix, Inc
  • 9.3.1. Company overview
  • 9.3.2. Key Executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
• 9.4. Thermo Fisher Scientific, Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key Executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
• 9.5. Malvern Instruments Ltd
  • 9.5.1. Company overview
  • 9.5.2. Key Executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
• 9.6. System Biosciences, Inc
  • 9.6.1. Company overview
  • 9.6.2. Key Executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
• 9.7. NX Pharmagen, Inc.
  • 9.7.1. Company overview
  • 9.7.2. Key Executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
• 9.8. Sistemic Ltd
  • 9.8.1. Company overview
  • 9.8.2. Key Executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
• 9.9. Capricor Therapeutics, Inc.
  • 9.9.1. Company overview
  • 9.9.2. Key Executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
• 9.10. Exiqon A/S
  • 9.10.1. Company overview
  • 9.10.2. Key Executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio